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patient and graft survival of 92.9% and 92.4% for biopsy arm, 97.9% and 94.1% 
for control arm. Both of the treatment arms were standard dose tacrolimus regimen. 
CONCLUSIONS: Three of immunosuppressive regimens are considered to have 
similar efﬁ cacy in short-term patient and graft survival in lower immunological risk 
renal transplant patients.
PUK5
CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS IN 
RENAL REPLACEMENT THERAPY IN SÃO PAULO, BRAZIL
Takemoto ML, Fernandes RA, Passos RB, Tolentino ACM, Takemoto MM, Moretti AIP, 
Cukier FN
ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: This study aims to describe clinical and demographic characteristics 
of end-stage renal disease (ESRD) patients on renal replacement therapy in the São 
Paulo state, Brazil. METHODS: Cross-sectional analysis of São Paulo renal replace-
ment therapy claims as reported in Brazilian Ambulatory Information System (SIA/
DATASUS) database in January 2009. Repeated records were excluded using identi-
ﬁ cation code, age, sex, and ﬁ rst treatment date as compatibility criteria. The following 
variables were investigated: diseases associated to ESRD, anemia, glucose levels, HCV, 
HbSAg, HIV, urea reduction ratio (URR), vascular access, and type of renal replace-
ment therapy. RESULTS: A total of 18,360 patients were identiﬁ ed among 18,886 
available claims, with a mean age of 54.23 years (SD = 15.53) and 57.7% male. 
Among 8,305 patients for whom secondary ICD-10 codes in addition to those related 
to renal failure itself were available, the more frequent conditions associated to ESRD 
were diabetes mellitus (17.5%), hypertension (26.4%) and glomerulonephritis 
(8.81%). Continuous Ambulatory Peritoneal Dialysis (CAPD) was the therapeutic 
strategy for 9.9% of patients compared to hemodialysis in 90.1%. 58.4% of all 
patients had hemodialysis vascular access and 50.9% had URR > 65%. Prevalence of 
positive HCV, HbSAg and HIV serology tests was 4.3%, 0.9% and 0.6%, respectively. 
Anemia and glucose levels > 126 were present for 45.4% and 19.6% of patients. The 
total amount paid for renal replacement therapy procedures in January 2009 in São 
Paulo state was 36,073,377 BRL. CONCLUSIONS: Although diabetes and hyperten-
sion renal complications can be prevented, they accounted for 43.9% of all conditions 
related to renal disease among the studied population. The ﬁ ndings also indicate that 
CAPD is still underused in Brazilian health care public system compared to other 
countries, as reported by previous local studies.
PUK6
POST RENAL TRANSPLANT PATIENT SURVIVAL AND THE COMBINED 
ADVERSE EFFECT OF POOR RENAL FUNCTION AND NEW ONSET 
DIABETES MELLITUS
McEwan P1, Baboolal K2
1CRC, Cardiff, UK; 2Cardiff and Vale NHS Trust, Cardiff, UK
OBJECTIVES: A major challenge in the ﬁ eld of renal transplantation is to prolong 
patient survival. Previous studies have demonstrated that renal function at 1 year is a 
major determinant of long term patient survival. Furthermore, the development of 
new onset diabetes after transplantation identiﬁ es patients at high risk of cardiovas-
cular events and mortality. This study aims to quantify any additive effect of impaired 
renal function and elevated glucose levels at 1 year post transplant on patient mortal-
ity. METHODS: Consecutive renal transplants from a single UK transplant centre 
over a 10 year period were analyzed using multivariate logistic regression in SPlus 8; 
the risk of patient mortality was assessed after stratiﬁ cation by renal function (mea-
sured by glomerular ﬁ ltration rate (GFR)) and impaired fasting glucose levels. 
RESULTS: Data were available on 307 patients with fasting glucose and GFR mea-
surements at 1 year post transplant. Overall 37% (n = 114) had a GFR of less than 
40 mL/minute and of these, 24% (n = 27) had fasting glucose levels greater than 
7 mmol/L. After adjusting for age, sex and donor factors patients with fasting glucose 
greater than 7 mmol/L and a GFR less than 40 mL/minute had a mortality odds ratio 
of 5.47 (P < 0.01) compared to those with glucose levels less than 5.6 mmol/l and a 
GFR greater than 40 mL/minute. CONCLUSIONS: This study demonstrates that the 
development of impaired fasting glucose post transplants is associated with a 35% 
increase risk of mortality and the development of new onset diabetes associated with 
a 2-fold increased risk. Our study further suggests that there is a negative synergistic 
effect of deteriorating renal function and progressive impaired glucose regulations on 
patient survival. Consequently, therapeutic strategies that could both improve GFR at 
one year and the incidence of diabetes might be expected to improve long term patient 
survival. 
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OBJECTIVES: To examine the pharmacy budget impact (PBI) of extending reimburse-
ment of non-calcium lanthanum carbonate (LC) to treatment of hyperphosphatemia 
(serum phosphorus > 1.78 mmol/L) in patients with chronic kidney disease pre-dialysis 
(CKD-ND) in France and the UK over ﬁ ve years. METHODS: The treated prevalence 
of CKD-ND and hyperphosphatemia, and the use of pharmacologic therapies, were 
estimated using published literature and EU nephrologist surveys. Drug costs were 
estimated from published sources. Market share changes were estimated from market 
research. Base-case analyses assumed complete medication compliance. Annual PBI 
was calculated as the difference in total drug costs between scenarios with and without 
the reimbursement extension for LC. Alternate scenarios and deterministic sensitivity 
analyses were also estimated. RESULTS: A small percentage of CKD-ND patients, 
14,500 (7%) and 64,600 (14.6%), are estimated as hyperphosphatemic in France and 
the UK, respectively. Of these patients, 81% in France versus 30% in the UK are 
estimated to receive phosphate binder therapy. CKD-ND market share for LC is 
estimated at 12% in France and 1–2% in the UK. The label extension, adding hyper-
phosphatemic CKD-ND patients, is estimated to increase LC use primarily at the 
expense of calcium-based phosphate binders. The annual PBI from the label extension 
is estimated to grow over Years 1–5 from 0 to c1.1 M in France; and to be <£25,000 
in Years 1–5 in the UK. Results are most sensitive to LC market share changes post-
label extension. CONCLUSIONS: The number of CKD-ND patients with hyperphos-
phatemia (>1.78 mmol/L) eligible for LC treatment is minimal in France and the UK. 
Assuming complete compliance, the annual PBI after 5 years of a label extension for 
LC to CKD-ND patients is estimated to be c1.1 M in France and <£25,000 in the 
UK. Calcium is the predominant therapy in CKD-ND; however, adding LC may result 
in a low pharmacy budget impact.
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OBJECTIVES: To determine the budget impact of Losartan + Aliskiren versus Losar-
tan in type 2 diabetes patients with hypertension and nephropathy in the Mexican 
Institute of Social Security (IMSS). METHODS: An annual budget impact analysis of 
the use of aliskiren in the treatment of diabetic nephropathy in the IMSS was made 
considering four scenarios: a) Losartan + Aliskireno; b) Losartan; c) real prevalence 
of diabetic nephropaty and d) estimated prevalence of diabetic nephropaty. The source 
of epidemiologic data was the Health National Survey (ENSA 2006). Information 
source to estimate health beneﬁ ts was AVOID study. Costing was performed through 
the technique of microcosting for replacement therapy with hemodialysis and perito-
neal dialysis. The use of resources was the standard IMSS supportive care, costs are 
in 2009 USD. There was no discount rate considered due to annual temporal horizon. 
a probabilistic and non-probabilistic sensitivity analysis was performed. RESULTS: 
Aliskiren alternative prevents the use of dialysis in the real scenario of 5,946 patients, 
with expected savings of $ 95,461,538.46 USD, while in the estimated alternative 
prevents dialysis in 11.765 with expected savings of $188,846,153.85 USD. CON-
CLUSIONS: Aliskiren use investment prevents up to 11,765 patients requiring dialysis 
with savings for the health sector of more than 188 million USD.
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OBJECTIVES: Effective management of chronic kidney disease (CKD)-associated 
anaemia has been established for all erythropoiesis-stimulating agents (ESAs). The aim 
of this study was to establish the real-life doses and comparative costs of both short-
acting ESAs and the newer longer-acting ESAs, darbepoetin alfa and the continuous 
erythropoietin receptor activator (C.E.R.A), and to forecast the impact of a change in 
current prescribing practice on health care budgets in Europe. METHODS: a retro-
spective chart review of CKD-associated anaemia management in 1014 pre-dialysis 
and 1016 dialysis patients was carried out by 261 nephrologists across the UK, Italy, 
Germany, Spain and France, between August 2008 and September 2009. Data col-
lected on ESA dosing were used to populate a UK budget impact model comparing 
current prescribing practice with speciﬁ c focus on C.E.R.A and darbepoetin alfa, over 
a ﬁ ve-year time horizon. Data on the number of patients, ESA market shares, and unit 
drug costs were derived from UK sources. RESULTS: The average monthly doses of 
ESAs in the combined ﬁ ve European markets (5EU) were as follows: epoetin alfa 
(pre-dialysis, 19,350 International Units (IU); dialysis, 35,404 IU); epoetin beta (pre-
dialysis, 18,230 IU; dialysis, 36,789 IU); darbepoetin alfa (pre-dialysis, 107 μg; dialy-
sis, 169 μg); C.E.R.A (pre-dialysis, 98 μg; dialysis, 150 μg). The model based on UK 
doses showed, that after ﬁ ve years, an increase in the use of C.E.R.A to 40% would 
reduce the overall ESA budget for CKD-associated anaemia by 15% compared to 
current prescribing practice. CONCLUSIONS: Based on real-life data, an increase in 
C.E.R.A prescribing may result in a cost-saving for the management of CKD-associ-
ated anaemia in the UK. This model can be applied to other European markets to 
forecast the local impact of a change in current prescribing practice.
